North Carolina-based Argos Therapeutics has filed a Securities and Exchange Commission registration relating to its proposed initial public offering of common stock to raise more than $86 million to help pay for clinical tests of an experimental treatment for kidney cancer. The company apparently reported a $9.2 million loss in 2010; it has been funded to date by $89 million from private investors and more than $70 million in government grants. According to a press report, the company is also developing experimental medicines to treat HIV, lupus and other diseases based on technology involving white blood cells and the creation of personalized therapies. See Argos Therapeutics News Release, July 29, 2011; (Durham) News Observer, July 30, 2011.